Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion

Blood

Volumn 102, Issue 10, 2003, Pages 3668-3674

  Kuppner, Maria C ^a   Scharner, Anabel ^b   Milani, Valeria ^b   Von Hesler, Christoph ^b   Tschöp, Katharina E ^b   Heinz, Oksana ^b   Issels, Rolf D ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYIFOSFAMIDE; GAMMA INTERFERON; GLUTATHIONE; IFOSFAMIDE; INTERLEUKIN 12; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ALLOGENEIC RESTRICTION; ARTICLE; CANCER PATIENT; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; ENZYME SPECIFICITY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INHIBITION KINETICS; INTERFERON PRODUCTION; INTRACELLULAR TRANSPORT; MONOCYTE; NATURAL KILLER CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

EID: 0242663270     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1408     Document Type: Article

References (43)

1. Brade WP, Herdrich K, Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985;12:1-47.
2. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994;26:439-456.
3. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2000;36:61-67.
4. Lind MJ, nMcGowan AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol. 1989;38:1835-1840.
5. Meier T, Allenbacher A, Mueller E, et al. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anticancer Drugs. 1994;5:405-409.
6. Multhoff G, Meier T, Botzler C, et al. Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels. Blood. 1995;85:2124-2131.
7. Botzler C, Kis K, Issels R, Multhoff G. A comparison of the effects of ifosfamide vs mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Exp Hematol. 1997;25:338-344.
8. Sladek NE. Oxazaphosphorines. In: Powis G, Prough RA, eds. Metabolism and Action of Anti-Cancer Drugs. London, United Kingdom: Taylor & Francis; 1987:48-90.
9. Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983;52:711-760.
10. Liang CM, Lee N, Cattell D, Liang M. Glutathione regulates interleukin-2 activity on cytotoxic cells. J Biol Chem. 1989;264:13519-13523.
11. Hamilos DL, Zelarney P, Mascali JJ. Lymphocyte proliferation in glutathione-depleted lymphocytes: direct relationship between glutathione availability and the proliferative response. Immunopharmacology. 1989;18:223-235.
12. Kavanagh TJ, Grossmann A, Jaecks EP, et al. Proliferative capacity of human peripheral blood lymphocytes sorted on the basis of glutathione content. J Cell Physiol. 1990;145:472-480.
13. Bilzer M, Lauterburg BH. Glutathione metabolism in activated human neutrophils: stimulation of glutathione synthesis and consumption of glutathione by reactive oxygen species. Eur J Clin Invest. 1991;21:316-322.
14. Desai A, Huang X, Warren JS. Intracellular glutathione redox status modulates MCP-1 expression in pulmonary granulomatous vasculitis. Lab Invest. 1999;79:837-847.
15. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, Machino T, Horie T. Intracellular glutathione regulates tumour necrosis factor-alpha induced p38 MAP kinase activation and RANTES production by human bronchial epithelial cells. Clin Exp Allergy. 2001;31:144-151.
16. Dodashi K, Aihara M, Araki T, et al. Regulation of LPS induced IL-12 production by IFN-gamma and IL4 through intracellular glutathione status in human alveolar macrophages. Clin Exp Immunol. 2001;124:290-296.
17. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998;95:3071-3076.
18. Hess SD, Egilinez NK, Bailey N, et al. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumor in situ by indirect effects of IFN-gamma. J Immunol. 2003;170:400-412.
19. Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 2002;48: 159-166.
20. Colaco C. Why are dendritic cells central to cancer immunotherapy. Mol Med Today. 1999;5: 14-17.
21. Kochman S, Bernard J. Antitumor immune response and cancer vaccination: the critical role of dendritic cells. Curr Med Res Opin. 1999;15:321-326.
22. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1999;392:245-252.
23. Reed DJ, Babson JR, Beatty PW, Brodie AE, Ellis WW, Potter DW. High performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide and related thiols and disufides. Anal Biochem. 1980;106:55-62.
24. Issels RD, Nagele A. Influence of thiols on thermosensitivity of mammalian cells in vitro. Methods Enzymol. 1990;186:696-708.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with phenol reagent. J Biol Chem. 1951;193:265-275.
26. Barnstable CJ, Jones EA, Crumpton MJ. Isolation, structure and genetics of HLA-A, -B and DRw(la) antigens. Br Med Bull. 1978;34:241-246.
27. Visseren MJ, Van Elsas A, Van der Voort El, et al. CTL specific for tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol. 1995;154:3991-3998.
28. Deneke SM, Farnberg BL. Regulation of cellular glutathione. Am J Physiol. 1989;257:163-173.
29. Wellner VP, Anderson ME, Puri RN, Jensen GI, Meister A. Radioprotection by glutathione ester: transport of glutathione ester into human lymphoid cells and fibroblasts. Proc Natl Acad Sci U S A. 1984;81:4732-4735.
30. Anderson ME, Powrie F, Puri P, Meister A. Glutathione monoethyl ester: preparation, uptake by tissues and conversion to glutathione. Arch Biochem Biophys. 1985;239:538-548.
31. Meister A. In: Glutathione Centennial: Molecular Properties and Clinical Applications. New York, NY: Academic Press; 1989.
32. Meister A, Tate SS. Glutathione and related gamma-glutamyl compounds: biosynthesis and utilization. Annu Rev Biochem. 1976;45:559-604.
33. Brock N. The oxazaphosphorines. Cancer Treat Rev. 1983(suppl A);10:3-15.
34. Kanto T, Hayashi N, Takehara T. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol. 1999;162:5584-5591.
35. Short S, Merkel BI, Caffrey R, McCoy KL. Defective antigen processing correlates with a low level of intracellular glutathione. Eur J Immunol. 1996; 26:3015-3020.
36. Chouab S, Chehimi J, Bani I, et al. Interleukin 12 induces the differentiation of major histocompatability complex class 1-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci U S A. 1994;91:12656-12663.
37. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory function in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994; 84:4008-4027.
38. Murata Y, Shimamura S, Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to distinctive cytokine production. Int Immunol. 2002;14:201-212.
39. Murata Y, Ohteki T, Koyasu S, Hamuro J. IFN-γ and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol. 2002;32:2866-2873.
40. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T. Depletion of total cysteine, glutathione and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol. 1994;35:132-136.
41. Pendyala L, Creaven PJ, Schwartz G, et al. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res. 2000;6: 1314-1321.
42. Gmunder H, Eck HP, Benninghoff B, Roth S, Droge W. Macrophages regulate intracellular glutathione levels of lymphocytes: evidence for an immunoregulatory role of cysteine. Cell Immunol. 1990;129:32-46.
43. Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A. 2002;99:1491-1495.